Carrick Therapeutics Overview

  • Founded

  • 2015

Founded
  • Status

  • Private

  • Employees

  • 23

Employees
  • Latest Deal Type

  • Series C

  • Latest Deal Amount

  • $19.5M

  • Investors

  • 10

Carrick Therapeutics General Information

Description

Developer of cancer therapeutics intended to transform cancer treatments and the lives of cancer patients. The company's therapeutics target molecular pathways that drive away aggressive and resistant forms of cancer using innovative mechanisms, enabling cancer patients to get their predictive biomarkers detected and get their treatments started from an early stage.

Contact Information

Website
www.carricktherapeutics.com
Formerly Known As
Navillus Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Therapeutic Devices
Primary Office
  • NovaUCD, Belfield Innovation Park
  • University College Dublin, Belfield
  • Dublin 4
  • Ireland

Carrick Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Carrick Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 03-Mar-2022 $19.5M 00000 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B2) 29-Jan-2021 000.00 00000 00000 Completed Clinical Trials - Phase 2
7. Secondary Transaction - Private 15-Mar-2021 00000 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series B1) 08-Nov-2019 000.00 00000 00000 Completed Startup
5. Secondary Transaction - Private 01-Mar-2019 00000 Completed Startup
4. Early Stage VC 28-Dec-2018 000.00 00000 000.00 Completed Startup
3. Early Stage VC (Series A) 18-Dec-2017 0000 00000 000.00 Completed Startup
2. Early Stage VC (Series A) 03-Oct-2016 $95M $95M Completed Startup
1. Seed Round 01-Jan-2015 Completed Startup
To view Carrick Therapeutics’s complete valuation and funding history, request access »

Carrick Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B2 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Series B1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Series A 24,002,052 $0.000100 $2.43 $2.43 1x $2.43 36.07%
Series A 2,057,612 $0.000100 $1.94 $1.94 1x $1.94 3.09%
To view Carrick Therapeutics’s complete cap table history, request access »

Carrick Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of cancer therapeutics intended to transform cancer treatments and the lives of cancer patients. The company's
Drug Discovery
Dublin, Ireland
23 As of 2021
00000
00.00 0000-00-00
00000000000 00000

000000

em ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
0000 000000000
Plymouth Meeting, PA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

0000 0

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000 000000000
South San Francisco, CA
000 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Carrick Therapeutics Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Geneos Therapeutics Venture Capital-Backed Plymouth Meeting, PA 00 000.00 00000000000 000.00
0000 000000 Venture Capital-Backed South San Francisco, CA 000 00000 00000000000 00000
0000000 0000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 0000000000 0 00.000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
You’re viewing 5 of 43 competitors. Get the full list »

Carrick Therapeutics Patents

  • 4

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Carrick Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202108572-D0 Therapeutic compounds and their use Pending 16-Jun-2021
AU-2020406056-A1 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl)piperidin-3-ol compounds and their therapeutic use Pending 16-Dec-2019 0000000000
CA-3159835-A1 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds and their therapeutic use Pending 16-Dec-2019 0000000000
GB-201918541-D0 Therapeutic compounds and their use Inactive 16-Dec-2019

Carrick Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Timothy Pearson Chief Executive Officer
Ash Bahl Chief Scientific Officer & Head of Research & Development
Stuart McIntosh Chief Medical Officer
Edward Ainscow Ph.D Vice President, Biology
George Golumbeski Ph.D Chairman
You’re viewing 5 of 8 executive team members. Get the full list »

Carrick Therapeutics Board Members (9)

Name Representing Role Since
Burt Adelman MD Self Board Member 000 0000
Christine Martin Cambridge Enterprise Board Member 000 0000
George Golumbeski Ph.D Self Chairman 000 0000
Jason Lettmann Lightstone Ventures Board Member 000 0000
Robert Tansley MD Cambridge Innovation Capital Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Carrick Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Carrick Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Rosetta Capital (UK) Venture Capital Minority 000 0000 000000 0
Revelation Partners Venture Capital Minority 000 0000 000000 0
Nortrust Nominees Limited Partner Minority 000 0000 000000 0
State Street Nominees Corporation Minority 000 0000 000000 0
Cambridge Innovation Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial